* Omeros Corp reported a quarterly adjusted loss of 56 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -60 cents. The mean expectation of three analysts for the quarter was for a loss of 70 cents per share. Wall Street expected results to range from -77 cents to -64 cents per share.
* Reported revenue was zero; analysts expected zero.
* Omeros Corp's reported EPS for the quarter was a loss of 56 cents.
* The company reported a quarterly loss of $32.23 million.
* Omeros Corp shares had risen by 7.3% this quarter and gained 30.3% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts was unchanged in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Omeros Corp is $43.00 This summary was machine generated from LSEG data November 14 at 04:19 a.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.70 -0.56 Beat
Jun. 30 2024 -1.14 -0.97 Beat
Mar. 31 2024 -0.58 -0.63 Missed
Dec. 31 2023 -0.55 -0.15 Beat
Comments